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Abstract 21 
 22 
Several MRI measures have been proposed as in vivo biomarkers of myelin, each 23 
with applications ranging from plasticity to pathology. Despite the availability of these 24 
myelin-sensitive modalities, specificity and sensitivity have been a matter of 25 
discussion. Debate about which MRI measure is the most suitable for quantifying 26 
myelin is still ongoing. In this study, we performed a systematic review of published 27 
quantitative validation studies to clarify how different these measures are when 28 
compared to the underlying histology. We analysed the results from 43 studies 29 
applying meta-analysis tools, controlling for study sample size and using interactive 30 
visualization (https://neurolibre.github.io/myelin-meta-analysis). We report the overall 31 
estimates and the prediction intervals for the coefficient of determination and find 32 
that MT and relaxometry-based measures exhibit the highest correlations with myelin 33 
content. We also show which measures are, and which measures are not statistically 34 
different regarding their relationship with histology.  35 
Abbreviations and mathematical symbols 36 
 37 
AD – axial diffusivity 38 
AK – axial kurtosis 39 
AWF – axonal water fraction 40 
FA – fraction anisotropy 41 
ihMTR – inhomogeneous magnetization transfer ratio 42 
k_fm – free water-macromolecular exchange rate 43 
k_mf – macromolecular-free water exchange rate 44 
M0m – macromolecular pool magnetization fraction 45 
MD – mean diffusivity 46 
MK – mean kurtosis 47 
MPF – macromolecular pool fraction 48 
MT – magnetization transfer 49 
MTR – magnetization transfer ratio 50 
MTR-UTE – magnetization transfer ratio (using ultra-short echo time) 51 
MTV – macromolecular tissue volume 52 
MVF-MT – myelin volume fraction (estimated from MT) 53 
MVF-T2 – myelin volume fraction (estimated from T2) 54 
MWF – myelin water fraction 55 
PD – proton density 56 
PN – peripheral nerve 57 
PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses 58 
QSM – quantitative susceptibility mapping 59 
R1f – free water pool longitudinal relaxation rate 60 
R2* – apparent transverse relaxation rate 61 
RAFF – relaxation along a fictitious field 62 
RD – radial diffusivity 63 
RD-DBSI – radial diffusivity (from diffusion basis spectrum imaging) 64 
RDe – extra-cellular compartment radial diffusivity 65 
RK – radial kurtosis 66 
rSPF – relative semi-solid proton fraction 67 
SC – spinal cord 68 
T1 – longitudinal relaxation time 69 
T1p – adiabatic longitudinal relaxation time 70 
T1sat – longitudinal relaxation time under magnetization transfer irradiation 71 
T2 – transverse relaxation time 72 
T2f – free water pool transverse relaxation time 73 
T2int – transverse relaxation intermediate component  74 
T2m – macromolecular pool transverse relaxation rate 75 
T2p – adiabatic transverse relaxation time 76 
  77 
Introduction 78 
Myelin is a key component of the central nervous system. The myelin sheaths 79 
insulate axons with a triple effect: allowing fast electrical conduction, protecting the 80 
axon, and providing trophic support (Nave & Werner, 2014). The conduction velocity 81 
regulation has become an important research topic, with evidence of activity-82 
dependent myelination as an additional mechanism of plasticity (Fields, 2015; 83 
Sampaio-Baptista & Johansen-Berg, 2017). Myelin is also relevant from a clinical 84 
perspective, given that demyelination is often observed in several neurological 85 
diseases such as multiple sclerosis (Höftberger & Lassmann, 2018). 86 
Given this important role in pathology and plasticity, measuring myelin in vivo has 87 
been an ambitious goal for magnetic resonance imaging (MRI) for more than two 88 
decades (A. Mackay et al., 1994; Rooney et al., 2007; G.J. Stanisz, Kecojevic, 89 
Bronskill, & Henkelman, 1999). Even though the thickness of the myelin sheath is in 90 
the order of micrometres, well beyond the MRI spatial resolution, its presence 91 
influences several physical properties that can be probed with MRI, from longitudinal 92 
and transversal relaxation phenomena to water molecule diffusion processes. 93 
However, being sensitive to myelin is not enough: to study how and why myelin 94 
content changes, it is necessary to define a specific biomarker. Interestingly, the 95 
quest for measuring myelin has evolved in parallel with an important paradigm shift 96 
in MRI research, where MRI data are no longer treated as just “pictures”, but as 97 
actual 3D distributions of quantitative measures. This perspective has breathed new 98 
life into an important field of research, quantitative MRI (qMRI), that encompasses 99 
the study of how to measure the relevant electromagnetic properties that influence 100 
magnetic resonance phenomena in biological tissues (Cercignani, Dowell, & Tofts, 101 
2018; Cohen-Adad & Wheeler-Kingshott, 2014). From the very definition of qMRI, it 102 
is clear that its framework applies to any approach for non-invasive myelin 103 
quantification. 104 
Similarly to other qMRI biomarkers, MRI-based myelin measurements are indirect, 105 
and might be affected by other microstructural features, making the relationship 106 
between these indices and myelination noisy. Assessing the accuracy of such 107 
measurements, and their sensitivity to change, is essential for their translation into 108 
clinical applications. Validation is therefore a fundamental aspect of their  109 
development (Cohen-Adad, 2018). The most common approach is based on 110 
acquiring MR data from in vivo or ex vivo tissue and then comparing those data with 111 
the related samples analysed using histological techniques. Despite being the most 112 
realistic approach, this comparison involves several methodological choices, from 113 
the specific technique used as a reference to the quantitative measure used to 114 
describe the relationship between MRI and histology. So far, a long list of studies 115 
have looked at MRI-histology comparisons (Cohen-Adad, 2018; Laule & Moore, 116 
2018; A. L. MacKay & Laule, 2016; Petiet et al., 2019), each of them focusing on a 117 
specific pathology and a few MRI measures. 118 
Despite these numerous studies, there is still an ongoing debate on what MRI 119 
measure should be used to quantify myelin and as a consequence there is a 120 
constant methodological effort to propose new measures. This debate would benefit 121 
from a quantitative analysis of all the findings published so far, specifically 122 
addressing inter-study variations and prospects for future studies, something that is 123 
currently missing from the literature. 124 
In this study, we systematically reviewed quantitative MRI-histology comparisons 125 
and we used meta-analysis tools to address the following question: how different are 126 
the modalities for myelin quantification in terms of their relationship with the 127 
underlying histology? 128 
 129 
Results 130 
Literature survey 131 
The screening process is summarized in the flowcharts in Figure 1 and Figure A1. 132 
The keywords as reported in the appendix returned 688 results on PubMed (last 133 
search on 03/06/2020). These results included 50 review articles. From the 50 134 
review articles, six were selected as relevant for both the topics of myelin and related 135 
MRI-histology comparisons (Cohen-Adad, 2018; Laule & Moore, 2018; Laule et al., 136 
2007; A. L. MacKay & Laule, 2016; Petiet et al., 2019; Turner, 2019). After the 137 
assessment, 58 original research studies were considered eligible, as shown in   138 
Table A1 (in the appendix) and Figure S2. All the data collected are available in the 139 
supplementary materials (Source Data 1). 140 
In terms of specific modalities, the survey shows that the most common MRI 141 
approach compared with histology was diffusion-weighted imaging (used in 28 142 
studies), followed by magnetization transfer (MT, 27 studies), T2 relaxometry (19 143 
studies) and T1 relaxometry (10 studies). Only 20 studies considered more than one 144 
approach: among the others, 20 focused exclusively on diffusion, 12 on MT, and 6 145 
on T2 relaxometry. 146 
 147 
 148 
Figure 1 – Sankey diagram representing the screening procedure (PRISMA flow 149 
chart provided in the appendix). To see the interactive figure: 150 
https://neurolibre.github.io/myelin-meta-analysis/01/selection.html#figure-1 151 
 152 
From these 58 studies, we then focused only on brain studies and we further 153 
excluded studies not reporting either the number of subjects or the number of ROIs 154 
per subject. We also excluded one single-subject study that relied on voxels as 155 
distinct samples, whereas the other studies in this review are based on ROIs (i.e. 156 
including more than one voxel). In the end, 43 suitable studies were identified for the 157 
subsequent analyses. 158 
 159 
Meta-analysis 160 
To compare the studies of interest, we first organized them according to the MRI 161 
measure used. Figure 2 and Figure 3 (and also Figure S3-S4) show the R2 values 162 
for the selected studies across measures: the highest values (R2>0.8) are obtained 163 
mostly from MT measures, but they are associated with small sample sizes (with an 164 
average of 32 sample points). The studies with largest sample sizes are associated 165 
with R2 values between 0.6 and 0.8 for MT and T2 relaxometry, but with lower values 166 
for T1 relaxometry and other approaches. 167 
To combine the results for each measure, we then used a mixed-effect model: in this 168 
way we were able to express the overall effect size in terms of a range of R2 values 169 
within a confidence interval, but also to assess prediction intervals and inter-study 170 
differences. The results are shown as forest plots in Figure 4 (and also Figure S5). 171 
Apart from MPF and MWF, all the measures showed R2 overall estimates in the 172 
range 0.21-0.53. To investigate the significance of the differences between 173 
measures, we conducted a repeated measures meta-regression on every R2 174 
estimate recorded (98 in total over 43 studies). As shown in Figure 5 (and also 175 
Figure S6), the measures can be roughly subdivided in two groups: MT- and 176 
relaxometry-based measures gave significantly higher R2 estimates compared to 177 
diffusion-based measures. Within the diffusion-based measures, FA shows slightly 178 
higher estimates than the others, with marginal significance over RD and AD or no 179 
significance in case of MD. 180 
Within MT- and relaxometry-based measures, the trends follow those in the forest 181 
plots (Figure 4), but most differences are not significant (Figure 5). However, the 182 
results in terms of z-score give a measure of distance between the R2 distributions. 183 
From this perspective, MPF has higher R2 estimates compared to all the other 184 
measures, but it is only marginally higher than MWF (z-score=0.77; p-value=1) so 185 
we cannot claim that one is superior to the other. Following the same reasoning, 186 
MTR and T1 are not statistically different (z-score=0.47; p-value=1). 187 
 188 
Figure 2 – Bubble chart of R2 values between a given MRI measure and histology for 189 
each study across MRI measures, with the area proportional to the number of 190 
samples. To see the interactive figure: https://neurolibre.github.io/myelin-meta-191 
analysis/02/closer_look.html#figure-3 192 
When considering the prediction intervals calculated using τ2 (the variance of the 193 
effect size parameters across the population of studies), for most measures the 194 
interval spanned from 0.1 to 0.9 (Figure 4 and Figure S5). This implies that future 195 
studies relying on such measures can expect, on the basis of these studies, to obtain 196 
any R2 value in this broad interval. The only exceptions were MPF (0.49-1) and MWF 197 
(0.45-0.95), whose intervals were narrower than the alternatives. Finally, I2 (a 198 
measure of how much of the variability in a typical study is due to heterogeneity in 199 
the experimental design) was generally quite high (Table 1). MWF showed the 200 
lowest I2 across measures (I2=73.19%), but this may be misleading considering that 201 
it was based on only 4 studies while the other measures included around 10 studies. 202 
Excluding MWF, MPF also showed a relatively low I2 (I2=83.18%). Qualitative 203 
comparisons across experimental conditions and methodological choices highlighted 204 
differences across pathology models, targeted tissue types and reference techniques 205 
(Figure 6 and Figure S7). Other factors such as magnetic field, co-registration, 206 
specific tissue and the related conditions (Figure S8) showed comparable 207 
distributions. 208 
 209 
 210 
Figure 3 – Treemap chart of the studies considered for the meta-analysis, organized 211 
by MRI measure. The color of each box represents the reported R2 value while the 212 
size box is proportional to the sample size. To see the interactive figure: 213 
https://neurolibre.github.io/myelin-meta-analysis/02/closer_look.html#figure-4 214 
 215 
 
MTR
MWF
T1
FA
RD
QSM R2*
MD
MPF
AD T2
RAFF
T2m
AWF
RK T1sat
MK MVF-MT MVF-T2
T1p
T2p
R1f k_mf
RDe
ihMTR
PD
rSPF
T2f k_fm
MTR-UTE
Fatemi et al., 2011
R 2 : 0.695
Measure: MTR
Number of subjects: 24.0
ROIs per subject: 25.0
Total number of samples: 600.0
Schmierer et al., 2007a
R 2 : 0.7055999999999999
Measure: MTR
Number of subjects: 37.0
ROIs per subject: 3.0
Total number of samples: 111.0
Lehto et al., 2017a
R 2 : 0.5169
Measure: MTR
Number of subjects: 20.0
ROIs per subject: 4.0
Total number of samples: 80.0
Hakkarainen et al., 2016
R 2 : 0.34
Measure: MTR
Number of subjects: 5.0
ROIs per subject: 12.0
Total number of samples: 60.0
Schmierer et al., 2004
R 2 : 0.7055999999999999
Measure: MTR
Number of subjects: 20.0
ROIs per subject: 3.0
Total number of samples: 60.0
Fjaer et al., 2013
R 2 : 0.338
Measure: MTR
Number of subjects: 54.0
ROIs per subject: 1.0
Total number of samples: 54.0
Lehto et al., 2017b
R 2 : 0.94
Measure: MTR
Number of subjects: 2.0
ROIs per subject: 16.0
Total number of samples: 32.0
Schmierer et al., 2008
R 2 : 0.4624
Measure: MTR
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tu et al., 2016
R 2 : 0.1444
Measure: MTR
Number of subjects: 25.0
ROIs per subject: 1.0
Total number of samples: 25.0
Fjaer et al., 2015
R 2 : 0.01
Measure: MTR
Number of subjects: 24.0
ROIs per subject: 1.0
Total number of samples: 24.0
Duhamel et al., 2019
R 2 : 0.78
Measure: MTR
Number of subjects: 3.0
ROIs per subject: 7.0
Total number of samples: 21.0
Jelescu et al., 2016
R 2 : 0.1024
Measure: MTR
Number of subjects: 21.0
ROIs per subject: 1.0
Total number of samples: 21.0
Beckmann et al., 2018
R 2 : 0.7668
Measure: MTR
Number of subjects: 20.0
ROIs per subject: 1.0
Total number of samples: 20.0
Tardif et al., 2012
R 2 : 0.36
Measure: MTR
Number of subjects: 1.0
ROIs per subject: 18.0
Total number of samples: 18.0
Zaaraoui et al., 2008
R 
2
 : 0 .6241000000000001
Measure: MTR
Number of subjects: 16.0
ROIs per subject: 1.0
Total number of samples: 16.0
Laule et al., 2006
R 2 : 0.67
Measure: MWF
Number of subjects: 13.0
ROIs per subject: 44.0
Total number of samples: 572.0
Laule et al., 2008
R 2 : 0.78
Measure: MWF
Number of subjects: 3.0
ROIs per subject: 73.0
Total number of samples: 219.0
West et al., 2018
R 2 : 0.66
Measure: MWF
Number of subjects: 15.0
ROIs per subject: 4.0
Total number of samples: 60.0
Hametner et al., 2018
R 2 : 0.3398
Measure: T1
Number of subjects: 6.0
ROIs per subject: 79.0
Total number of samples: 474.0
Schmierer et al., 2007a
R 2 : 0.4760999999999999
Measure: T1
Number of subjects: 37.0
ROIs per subject: 3.0
Total number of samples: 111.0
Hakkarainen et al., 2016
R 2 : 0.77
Measure: T1
Number of subjects: 5.0
ROIs per subject: 12.0
Total number of samples: 60.0
Schmierer et al., 2004
R 2 : 0.48999999999999994
Measure: T1
Number of subjects: 20.0
ROIs per subject: 3.0
Total number of samples: 60.0
Reeves et al., 2016
R 2 : 0.27
Measure: T1
Number of subjects: 13.0
ROIs per subject: 3.0
Total number of samples: 39.0
Schmierer et al., 2008
R 2 : 0.7921
Measure: T1
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tardif et al., 2012
R 2 : 0.5929
Measure: T1
Number of subjects: 1.0
ROIs per subject: 18.0
Total number of samples: 18.0
Lehto et al., 2017a
R 2 : 0.2237
Measure: FA
Number of subjects: 20.0
ROIs per subject: 4.0
Total number of samples: 80.0
Abe et al., 2019
R 2 : 0.1024
Measure: FA
Number of subjects: 5.0
ROIs per subject: 12.0
Total number of samples: 60.0
Chang et al., 2017
R 2 : 0.1989
Measure: FA
Number of subjects: 4.0
ROIs per subject: 14.0
Total number of samples: 56.0
Janve et al., 2013
R 2 : 0.0729
Measure: FA
Number of subjects: 8.0
ROIs per subject: 6.0
Total number of samples: 48.0
Schmierer et al., 2007b
R 2 : 0.6241000000000001
Measure: FA
Number of subjects: 16.0
ROIs per subject: 3.0
Total number of samples: 48.0
Jito et al., 2008
R 2 : 0.7327
Measure: FA
Number of subjects: 36.0
ROIs per subject: 1.0
Total number of samples: 36.0
Wendel et al., 2018
R 2 : 0.5707
Measure: FA
Number of subjects: 12.0
ROIs per subject: 3.0
Total number of samples: 36.0
Schmierer et al., 2008
R 2 : 0.6889
Measure: FA
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tu et al., 2016
R 2 : 0.0169
Measure: FA
Number of subjects: 25.0
ROIs per subject: 1.0
Total number of samples: 25.0
Yano et al., 2018
R 
2
 : 0.7569
Measure: FA
Number of subjects: 21.0
ROIs per subject: 1.0
Total number of samples: 21.0
Chandran et a l., 2012
R 2 : 0.5
Measure: FA
Number of subjects: 20.0
ROIs per subject: 1.0
Total number of samples: 20.0
Mollink et al., 2019
R 
2
 : 0.2704
Measure: FA
Number of subjects: 18.0
ROIs per subject: 1.0
Total number of samples: 18.0
Aojula e t al., 2016
R 2 : 0.1197
Measure: FA
Number of subjects: 17.0
ROIs per subject: 1.0
Total number of samples: 17.0
Wan g et al.,  2 009
R  : 0.46 37
Mea sure : FA
N um ber o f sub jec ts: 15 .0
RO Is per sub jec t:  1.0
T otal nu m ber of  sam ples : 1 5.0
Pol et al., 2019
R  : 0.0576
Measure: FA
Number of subjec ts: 11.0
ROIs per  subject: 1.0
Total number of samples: 11.0
Thiessen  et al ., 2013
R  : 0.7056
Mea sur e: FA
Number  of subjects:  10.0
ROIs per  sub jec t: 1.0
Total  number of samples: 10.0
Lehto et al., 2017a
R 2 : 0.0015
Measure: RD
Number of subjects: 20.0
ROIs per subject: 4.0
Total number of samples: 80.0
Kelm et al., 2016
R 2 : 0.1369
Measure: RD
Number of subjects: 13.0
ROIs per subject: 6.0
Total number of samples: 78.0
Abe et al., 2019
R 2 : 0.1681
Measure: RD
Number of subjects: 5.0
ROIs per subject: 12.0
Total number of samples: 60.0
Chang et al., 2017
R 2 : 0.038
Measure: RD
Number of subjects: 4.0
ROIs per subject: 14.0
Total number of samples: 56.0
Janve et al., 2013
R 2 : 0.2401
Measure: RD
Number of subjects: 8.0
ROIs per subject: 6.0
Total number of samples: 48.0
Wendel et al., 2018
R 2 : 0.2973
Measure: RD
Number of subjects: 12.0
ROIs per subject: 3.0
Total number of samples: 36.0
Schmierer et al., 2008
R 
2
 : 0.6561
Measure: RD
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tu et al., 2016
R 
2
 : 0.2116
Measure: RD
Number of subjects: 25.0
ROIs per subject: 1.0
Total number of samples: 25.0
Jelescu et al., 2016
R 2 : 0.5041
Measure: RD
Number of subjects: 21.0
ROIs per subject: 1.0
Total number of samples: 21.0
Yano et al., 2018
R 2 : 0.8281
Measure: RD
Number of subjects: 21.0
ROIs per subject: 1.0
Total number of samples: 21.0
Chandran et al., 2012
R 2 : 0.34
Measure: RD
Number of subjects: 20.0
ROIs per subject: 1.0
Total number of samples: 20.0
Aojula et al., 2016
R 2 : 0.2097
Measure: RD
Number of subjects: 17.0
ROIs per subject: 1.0
Total number of samples: 17.0
Hametner et al., 2018
R 2 : 0.1239
Measure: QSM
Number of subjects: 6.0
ROIs per subject: 79.0
Total number of samples: 474.0
Hametner et al., 2018
R 2 : 0.0007
Measure: R2*
Number of subjects: 6.0
ROIs per subject: 79.0
Total number of samples: 474.0
Lehto et al., 2017a
R 2 : 0.3492
Measure: MD
Number of subjects: 20.0
ROIs per subject: 4.0
Total number of samples: 80.0
Kelm et al., 2016
R 2 : 0.1225
Measure: MD
Number of subjects: 13.0
ROIs per subject: 6.0
Total number of samples: 78.0
Chang et al., 2017
R 2 : 0.0129
Measure: MD
Number of subjects: 4.0
ROIs per subject: 14.0
Total number of samples: 56.0
Janve et al., 2013
R 2 : 0.0784
Measure: MD
Number of subjects: 8.0
ROIs per subject: 6.0
Total number of samples: 48.0
Schmierer et al., 2007b
R 2 : 0.4624000000000001
Measure: MD
Number of subjects: 16.0
ROIs per subject: 3.0
Total number of samples: 48.0
Wendel et al., 2018
R 2 : 0.0564
Measure: MD
Number of subjects: 12.0
ROIs per subject: 3.0
Total number of samples: 36.0
Schmierer et al., 2008
R 2 : 0.6084
Measure: MD
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tu et al., 2016
R 2 : 0.0289
Measure: MD
Number of subjects: 25.0
ROIs per subject: 1.0
Total number of samples: 25.0
Yano et al., 2018
R 2  : 0.5329
Measure: MD
Number of subjects: 21.0
ROIs per subject: 1.0
Total number of samples: 21.0
Ao ju la  et al., 2016
R  : 0 .24 5
Mea sure : MD
Numb er  o f subje ct s:  17 .0
RO Is per  sub je ct: 1 .0
Tota l n umber  o f samp les:  17 .0
Pol et al., 2019
R 2 :  0.3481
Measure: M D
Number of  subjects: 11.0
ROIs per subject: 1.0
Total number of samp les: 11.0
Thiessen et al.,  2013
R  : 0.6561
Measure: MD
Number of  subjects: 10.0
ROIs per subjec t: 1.0
Total number of samples: 10.0
Khodanovic et al., 2017
R 2 : 0.779
Measure: MPF
Number of subjects: 14.0
ROIs per subject: 8.0
Total number of samples: 112.0
Schmierer et al., 2007a
R 2 : 0.6400000000000001
Measure: MPF
Number of subjects: 37.0
ROIs per subject: 3.0
Total number of samples: 111.0
West et al., 2018
R 2 : 0.7
Measure: MPF
Number of subjects: 15.0
ROIs per subject: 4.0
Total number of samples: 60.0
Janve et al., 2013
R 2 : 0.7225
Measure: MPF
Number of subjects: 8.0
ROIs per subject: 6.0
Total number of samples: 48.0
Schmierer et al., 2008
R 2 : 0.7396
Measure: MPF
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Souste lle et a l.,  2019
R  :  0 .7569
Mea sur e:  M PF
Nu m be r o f sub je cts: 15 .0
RO Is per  sub ject : 1 .0
To ta l numb er  o f sam ples:  15. 0
Tura ti  et  al ., 2015
R  :  0 .287 2
M ea sur e:  MPF
Numb er  o f sub ject s: 15 .0
ROI s pe r sub ject : 1 .0
To ta l n umb er  of sa m ples:  15.0
Khodanovic et a l., 2019
R 2 : 0.82
Measure: MPF
Number of subjects: 13.0
ROIs per subject: 1.0
Total number of samples: 13.0
Th iesse n e t a l., 2013
R  : 0 .8649
Mea sur e:  M PF
Nu m be r o f sub je cts: 10 .0
RO Is per  sub ject : 1 .0
To ta l numb er  o f sam ples:  10. 0
Lehto et al., 2017a
R 2 : 0.4199
Measure: AD
Number of subjects: 20.0
ROIs per subject: 4.0
Total number of samples: 80.0
Abe et al., 2019
R 2 : 0.0121
Measure: AD
Number of subjects: 5.0
ROIs per subject: 12.0
Total number of samples: 60.0
Chang et al., 2017
R 2 : 0.1482
Measure: AD
Number of subjects: 4.0
ROIs per subject: 14.0
Total number of samples: 56.0
Janve et al., 2013
R 2 : 0.0064
Measure: AD
Number of subjects: 8.0
ROIs per subject: 6.0
Total number of samples: 48.0
Wendel et al., 2018
R 2 : 0.1987
Measure: AD
Number of subjects: 12.0
ROIs per subject: 3.0
Total number of samples: 36.0
Schmierer et al., 2008
R 
2
 : 0.64
Measure: AD
Number of subjects: 15.0
ROIs per subject: 2.0
Total number of samples: 30.0
Tu et al ., 2016
R  2 : 0 .0001
Measure: AD
Number of subjects: 25.0
ROIs per subject: 1.0
Total number of sam ples:  25.0
Aojula et al., 2016
R 2 : 0.1296
Measure: AD
Number of subjects: 17.0
ROIs per subject: 1.0
Total number of samples: 17.0
T hiessen et al., 2013
R  :  0 .5625
M easure:  AD
Num ber of subjects:  10.0
ROIs per subject: 1 .0
T otal nu mber of sample s:  10.0
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Figure 4 – Forest plots showing the R2 values reported by the studies and estimated 217 
from the mixed-effect model for each measure. The hourglasses and the dotted lines 218 
in the mixed-effect model outcomes represent the prediction intervals. 219 
To see the interactive figure: https://neurolibre.github.io/myelin-meta-220 
analysis/03/meta_analysis.html#figure-5  221 
Discussion 222 
Indirect measures are the most popular (for better or worse) 223 
The literature survey offers an interesting perspective on popular research trends 224 
(Figure S2). The first consideration one can make is that every myelin imaging 225 
technique achieves myelin sensitivity through different means. A clear example is 226 
offered by the two most common approaches in this meta-analysis, DWI and MT: the 227 
MT effect is driven by saturation pulses interacting with myelin macromolecules that 228 
transfer their magnetization to water, whereas in diffusion experiments myelin is just 229 
not part of the picture. Diffusion acquisitions are blind to direct myelin measurement 230 
because the TEs used are too long (~100ms) to be influenced by the actual 231 
macromolecules – with T2 of ~10us (G.J. Stanisz et al., 1999) – or even the water 232 
molecules trapped in the myelin sheath – with T2 of ~30ms (A. Mackay et al., 1994). 233 
To infer myelin content, one needs to rely on the interaction between intra-cellular 234 
and extra-cellular water compartments. The majority of diffusion studies included in 235 
this analysis used tensor-based measures (with fractional anisotropy being the most 236 
common), but some also used kurtosis-based analysis. The main issue with this 237 
approach is that other factors affect those measures (Beaulieu, 2002, 2009), making 238 
it difficult to specifically relate changes in water compartments to changes in myelin.  239 
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Figure 5 – Results from the repeated measures meta-regression, displayed in terms 
of z-scores (left) and p-values (right) for each pairwise comparison across all the MRI 
measures. In the z-score heatmap, each element refers to the comparison between 
the measure on the x axis with the one on the y axis. For example, MPF and FA (z-
score=7.14; p-value<0.0001) are statistically different, while MPF and T1 (z-
score=2.51; p-value=0.43) are not statistically different. To see the interactive figure: 
https://neurolibre.github.io/myelin-meta-analysis/03/meta_analysis.html#figure-6 
 240 
Figure 6 – Experimental conditions and methodological choices influencing the R2 241 
values (top: reference techniques; middle: pathology model; bottom: tissue types). 242 
To see the interactive figure: https://neurolibre.github.io/myelin-meta-243 
analysis/04/other_factors.html#figure-7 244 
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MEASUR
E 
NUMBER OF 
STUDIES 
ESTIMAT
E 
STANDARD 
ERROR 
TAU2 I2 
MTR 16 0.508 0.0691 0.07 96.03% 
MPF 10 0.7657 0.0455 0.0128 83.18% 
FA 17 0.3766 0.0663 0.0652 87.49% 
RD 15 0.3364 0.0679 0.0615 92.30% 
MD 12 0.2639 0.0679 0.044 87.35% 
T1 8 0.5321 0.0692 0.0328 86.51% 
AD 9 0.2095 0.0802 0.048 97.69% 
T2 7 0.3938 0.1023 0.0651 84.49% 
MWF 4 0.6997 0.0432 0.0041 73.19% 
Table 1 Results from the mixed-effect models: for each measure we reported the 247 
number of studies, the estimate and standard error of the overall R2 distribution, the 248 
τ2 and the I2. 249 
 250 
Despite this issue, the use of diffusion as a proxy for myelin is quite widespread, 251 
specifically outside the field of quantitative MRI. This is probably a consequence of 252 
how popular DWI has become and how widely available are the related acquisition 253 
sequences. MT, the second most popular technique for quantifying myelin, estimates 254 
myelin by acquiring data with and without saturating the macromolecular proton pool. 255 
The simplest MT measure, MT ratio (MTR), incorporates non-myelin contributions in 256 
the final measurement. Recent acquisition variations include computing MTR from 257 
acquisitions with ultra-short echo times (Du, Takahashi, Bydder, Chung, & Bydder, 258 
2009; Guglielmetti et al., 2020; Wei et al., 2018) or relying on inhomogeneous MT 259 
(Duhamel et al., 2019; Varma, Duhamel, de Bazelaire, & Alsop, 2015). More 260 
complex experiments, e.g. quantitative MT, are based on fitting two compartments to 261 
the data, the free water and the macromolecular compartments, or pools. In this way, 262 
one is able to assess myelin through MPF with higher specificity, although still 263 
potentially including contributions from other macromolecules. Additional measures 264 
have also been considered (including the T2 of each pool, the exchange rate 265 
between the pools). The drawback of qMT is the requirement for a longer and more 266 
complex acquisition. Recently there have been alternative techniques to estimate 267 
only MPF, resulting in faster acquisitions with similar results (M. Khodanovich et al., 268 
2019; M. Y. Khodanovich et al., 2017; Yarnykh, 2012). Despite being focused on 269 
macromolecular contributions, these approaches are not strictly specific to myelin 270 
(Sled, 2018): in this sense, an important limitation is that MT effects are sensitive to 271 
the pH of the targeted tissue and therefore changes in the pH (caused for example 272 
by inflammation processes) will affect MT-based measures of myelin (Greg J. 273 
Stanisz, Webb, Munro, Pun, & Midha, 2004).  274 
Following diffusion and MT, the most popular approach is T2 relaxometry. Unlike 275 
diffusion and MT, in T2 relaxometry experiments one can directly observe the 276 
contribution from the water trapped between the myelin bilayers, and can therefore 277 
estimate the myelin water fraction. A simpler but less specific approach consists in 278 
estimating the transverse relaxation time considering the decay to be mono-279 
exponential. A historical and practical drawback of these approaches is that they 280 
require longer acquisitions, although faster alternatives have been developed (Does 281 
& Gore, 2000; Prasloski et al., 2012). A more subtle but nevertheless important 282 
limitation lies in the multi-compartment model used in multi-exponential T2 283 
relaxometry (Does, 2018): this model generally assumes slow water exchange 284 
between compartments, but it has been showed that water exchange actually 285 
contributes to T2 spectra variations (Dula, Gochberg, Valentine, Valentine, & Does, 286 
2010; Kevin D. Harkins, Dula, & Does, 2012). 287 
Finally, other studies used a diverse collection of other measures, including T1 288 
relaxometry, apparent transversal relaxation rate (R2*), proton density (PD), 289 
macromolecular tissue volume (MTV), relaxation along a fictitious field (RAFF), and 290 
quantitative susceptibility mapping (QSM). 291 
After this general overview, it is clear that each modality could be a suitable 292 
candidate for a quantitative myelin biomarker. To then make a choice informed by 293 
the studies here reported, it becomes necessary to consider not only effect sizes in 294 
terms of correlation, but also sample sizes and acquisition times. 295 
 296 
There is no myelin MRI measure true to histology  297 
When looking at the R2 values across the different measures, the first detail that 298 
catches one’s eye is how most measures present a broad range of values (Figure 2 299 
and Figure 3). When taking into account the sample size, the largest studies show 300 
higher correlations for MT and T2 relaxometry studies than any other approach 301 
(Figure S3 and Figure S4). In quantitative terms, the meta-analysis corroborates this 302 
idea, showing that MPF and MWF tend to be more specific to myelin compared to 303 
the other measures (respectively with R2=0.7657 and R2=0.6997), in line with the 304 
underlying theory. Notably, diffusion-based measures show the lowest overall 305 
estimates (with values between R2=0.3766 for FA and R2=0.2095 for AD): this could 306 
be due to the fact, as already mentioned, that DWI does not specifically measure 307 
myelin properties, and despite FA and RD being influenced by the myelin content, 308 
they are also influenced by other factors that make them unsuitable as measures of 309 
myelin. The repeated measure meta-regression confirms this overall picture, clearly 310 
distinguishing MT- and relaxometry-based measures from diffusion-based ones 311 
(Figure 5). 312 
Despite these considerations on the advantages of MPF and MWF, one should 313 
refrain from concluding that they are the “true” MRI measures of myelin. The reason 314 
for this caution is given not by the overall effect sizes observed here, but by the 315 
collateral outcomes of the meta-analysis. The first one is given by the prediction 316 
intervals: most measures exhibit large intervals (Figure 4), not supporting the idea of 317 
them being robust biomarkers. MPF and MWF seem to be again the most suitable 318 
choices for future studies, but a range between 0.5 and 1 is still quite large. 319 
The second important aspect to consider is given by the differences across studies: 320 
the meta-analysis showed how such differences strongly limit inter-study 321 
comparisons for a given measure (Figure 6). This result should be expected, given 322 
that the studies here examined are inevitably influenced by the specific experimental 323 
constraints and methodological choices. Given the limited number of studies, it is not 324 
possible to quantitatively study interactions between MRI measures and the other 325 
factors (e.g. modality used as a reference, tissue types, magnetic field strength). For 326 
further qualitative insights, we invite the reader to explore the interactive figures S7-327 
S8. A first important factor to consider is the validation modality used as a reference, 328 
which will be dictated by the equipment availability and cost. However, such a choice 329 
has an impact on the actual comparison: histology and immunochemistry, despite 330 
being specific to myelin, do not offer a volumetric measure of myelin, but rather a 331 
proxy based on the transmittance of the histological sections. So far, the only 332 
modality able to give a volumetric measure would be electron microscopy, which is 333 
an expensive and resource-consuming approach. Also, electron microscopy has 334 
several limitations, including tissue shrinkage, degradation of the myelin sheath 335 
structure due to imperfect fixation, imperfect penetration of the osmium stain, 336 
polishing, keeping focus over large imaging regions. All these effects contribute to 337 
the lack of precision and accuracy when quantifying myelin content with EM-based 338 
histology (Cohen-Adad, 2018). Another important observation is that none of the 339 
studies here reviewed considered histology reproducibility, which is hard to quantify 340 
as a whole given that a sample can be processed only once: collateral factors 341 
affecting tissue processing (e.g. sectioning distortions, mounting and staining issues) 342 
constitute an actual limitation for histology-based validation. A further example of 343 
influential factor often dictated by equipment availability is the magnetic field strength 344 
of the MRI scanner: figure S8 shows that most studies were conducted at 7T and 345 
9.4T, with some pioneering studies at 1.5T and even fewer ones at other field 346 
strengths. 347 
In addition to differences in experimental and methodological designs, there are also 348 
several considerations that arise out of the lack of shared practices in MRI validation 349 
studies. The first evident one is the use of correlations: despite being a simple 350 
measure that serves well the purpose of roughly characterizing a relationship, 351 
Pearson correlation is not the right tool for quantitative biomarkers, as it does not 352 
characterize the actual relationship between histology and MRI. Linear regression is 353 
a step forward but has the disadvantage of assuming a linear relationship. Despite 354 
Pearson correlation and linear regression being the most common measures used in 355 
the studies here reviewed, it is still not clear if the relationship is actually linear. Only 356 
one study among the considered ones computed both Pearson and Spearman 357 
correlation values (Tardif, Bedell, Eskildsen, Collins, & Pike, 2012), and reported 358 
higher Spearman correlations, pointing out that non-linear relationships should 359 
actually be considered. One last consideration regarding the use of correlation 360 
measures for validating quantitative biomarkers is about the intercept in the MRI-361 
histology relationship. Notably, only MWF is expected to assume a value equal to 362 
zero when myelin is absent (West et al., 2018). For the other measures, it would be 363 
necessary to estimate the intercept, which leads to the calibration problem in the 364 
estimate of myelin volume fraction. Notably, calculating Pearson correlation does not 365 
provide any information for such calibration. Another arbitrary practice that would 366 
benefit from some harmonization is the choice of ROIs. The studies reported here 367 
examined a diverse list of ROIs, in most cases hand-drawn on each modality, 368 
encompassing different types of tissue, and the most common approach is to report 369 
a single, pooled correlation. This is problematic, as different types of tissue (e.g. grey 370 
matter and white matter) will show different values for MRI-based measures but also 371 
for histology-based ones, making linearity assumptions about the two modalities. 372 
However, with this approach gross differences between tissues drive the observed 373 
correlation, without actually showing if the MRI-based measure under analysis is 374 
sensitive to subtle differences and therefore a suitable quantitative biomarker for 375 
myelin. The effect of considering different types of tissues is showed in Figure 6 and 376 
Figure S7, where correlation ranges change when considering different types of 377 
tissue. However, the large correlation range in white matter, the most common tissue 378 
studied, suggests that other factors also affect the correlation. 379 
It should be clear at this point that any debate about a universal MRI-based measure 380 
of myelin is pointless, at least at the moment, as the overall picture provided by 381 
previous studies does not point to any such ideal measure. Nevertheless, is debating 382 
about a universal measure helpful for future studies? 383 
 384 
Better biomarkers require more reproducibility studies  385 
We hope this meta-analysis convinces the reader that a holy grail of myelin imaging 386 
does not exist, at least as long as we consider histology to be the ground truth. 387 
Given that we all have to pick our poison, the upside is that measures based on MT 388 
and relaxometry are not statistically different, and therefore future studies have an 389 
actual choice among candidate measures. For further progress, rather than debating 390 
about a perfect measure, we would argue that what is missing at the moment is a 391 
clear picture of what can be achieved with each specific MRI modality. The studies 392 
examined here focus on a large set of different measures, and more than half of 393 
them considered at most two measures, highlighting how the field is mostly focused 394 
on formulating new measures. While it is understood that novel measures can 395 
provide new perspectives, it is also fundamentally important to understand the 396 
concrete capabilities and limitations of current measures. From this meta-analysis, 397 
what the literature clearly lacks is reproducibility studies, specifically answering two 398 
main questions: (1) what is the specificity of each measure? We should have a 399 
practical validation of our theoretical understanding of the relevant confounds; (2) 400 
what is the “parameter sensitivity” of each measure? Here we refer to parameter 401 
sensitivity in a broad sense, that includes also experimental conditions and 402 
methodological choices. The results here presented show how certain conditions 403 
(e.g. pathology) seem to affect the coefficient of determination more than others but 404 
given the limited number of studies for each modality, we refrained from additional 405 
analyses to avoid speculation. A warning message that is evident from these results 406 
is the inherent limitation of DWI for estimating myelin content: this is not by any 407 
means a novel result (Beaulieu, 2002, 2009), but it is nevertheless worth reiterating 408 
given the outcomes of our analysis. If estimating myelin content is relevant in a 409 
diffusion study, it is important to consider complementing the diffusion measure with 410 
one of the modalities here reviewed; in this way, it would be possible to decouple the 411 
influence of myelin content from the many other factors that come into play when 412 
considering diffusion phenomena. 413 
Finally, an important factor to take into account when choosing a biomarker of myelin 414 
is the actual application. For animal research, long acquisitions are not a major 415 
issue. However, when considering biomarkers for potential clinical use, the 416 
acquisition time can become a relevant issue. An example is the well-established 417 
multi-echo spin-echo implementation of MWF, that can only be used for a specific 418 
slice in a hypothetical clinical scenario. Faster techniques have been proposed for 419 
estimating it with gradient- and spin-echo (GRASE) sequences (Does & Gore, 2000; 420 
Feinberg & Oshio, 1991; Prasloski et al., 2012). Even in this case, the acquisition 421 
time still reaches 15 minutes for acquiring roughly the whole brain with an isotropic 422 
resolution of 2mm. Complex MT acquisitions such as qMT suffer from the same 423 
problem, although it is possible to use optimized and faster protocols to focus 424 
specifically on MPF (M. Khodanovich et al., 2019; M. Y. Khodanovich et al., 2017; 425 
Yarnykh, 2012). 426 
 427 
Conclusions 428 
Several MRI measures are sensitive to myelin content and the current literature 429 
suggests that most of them are not statistically different in terms of their relationship 430 
with the underlying histology. Measures highly correlated with histology are also the 431 
ones with a higher expected specificity. This suggests that future studies should try 432 
to better address how specific each measure is, for the sake of clarifying suitable 433 
applications. 434 
Methods 435 
Review methodology 436 
The Medline database (https://pubmed.ncbi.nlm.nih.gov) was used to retrieve the 437 
articles. The keywords used are specified in the appendix. We followed the PRISMA 438 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines 439 
for record screening and study selection. The results were first screened to remove 440 
unrelated work. Specifically we discarded: work relying only on MRI; work relying 441 
only on histology or equivalent approaches; work reporting only qualitative 442 
comparisons. After this first screening, the remaining papers were assessed. At this 443 
stage, we discarded: studies using MRI-based measures in arbitrary units (e.g. T1-444 
weighted or T2-weighted data); studies using measures of variation in myelin content 445 
(defined either as the difference between normal and abnormal myelin content) 446 
either for MRI or for histology; studies using arbitrary assessment scales; studies 447 
comparing MRI-based absolute measures of myelin with histology-based relative 448 
measures (e.g. g-ratio); studies reporting other quantitative measures than 449 
correlation or R2 values; studies comparing histology from one dataset and MRI from 450 
a different one. As an additional source for potential candidate studies, we screened 451 
the review articles in the initial results, and we selected the relevant studies that 452 
were not already present in the studies already selected. 453 
From the final papers, we collected first the following details: the DOI; which 454 
approach was used (diffusion, MT, T1 relaxometry, T2 relaxometry, or other); which 455 
specific MRI measures were compared to histology or equivalent techniques; the 456 
magnetic field; the technique used as a reference (histology, immunochemistry, 457 
microscopy, electron microscopy); the focus of the study in terms of brain, spinal 458 
cord or peripheral nerve; if the subjects were humans or animals, and if the latter 459 
which animal; if the tissue under exam was in vivo, in situ or ex vivo, and in the latter 460 
case if the tissue was fixed or not; if the tissue was healthy or pathological, and if the 461 
latter which pathology; the specific structures examined for correlation purposes; 462 
which comparison technique was used (e.g. Pearson correlation, Spearman 463 
correlation, linear regression); the number of subjects; the number of ROIs per 464 
subject; the male/female ratio; if registration procedures were performed to align MRI 465 
and histology; in case of pathological tissue, if control tissue was considered as well; 466 
other relevant notes. If before calculating the correlations the data were averaged 467 
across subjects, the number of subjects was considered to be one. The same 468 
consideration was made for averaging across ROIs. This is because the numbers of 469 
subjects and ROIs were used to take into account how many sample points were 470 
used when computing the correlation. We set each of those numbers to 1 for all the 471 
studies where the data were averaged respectively across subjects and across 472 
ROIs. Finally, in those cases where the number of ROIs or the number of subjects 473 
were given as a range rather than specific values, we used the most conservative 474 
value and added the related details to the notes. 475 
We then proceeded to collect the quantitative results reported for each measure and 476 
for each study in the form of R2. Given that different studies may rely on a different 477 
strategy when reporting correlations, we adopted the following reasoning to limit 478 
discrepancies across studies while still objectively representing each of them. In 479 
case of multiple correlation values reported, for our analysis we selected the ones 480 
referring to the whole dataset and the entire brain if available, and considering each 481 
ROI in a given subject as a sample if possible; if only correlation values for specific 482 
ROIs were reported, the one for the most common reported structure would be 483 
chosen. In the case of multiple subjects, if data were provided separately for each 484 
group, the correlation for the control group was used. When different comparison 485 
methods were reported (e.g. both Pearson and Spearman correlation) or if the MRI 486 
data was compared with multiple references (e.g. both histology and 487 
immunohistochemistry), the correlations used were chosen on the basis of the 488 
following priority orders (from the most preferable to the least): for multiple 489 
comparison methods, linear regression, Spearman correlation, Pearson correlation; 490 
for multiple reference techniques, electron microscopy, immunohistochemistry, 491 
histology. Finally, in any other case where more than one correlation value was 492 
available, the most conservative value was used. Any other additional value was in 493 
any case mentioned in the notes of the respective study. 494 
 495 
Meta-analysis 496 
For the quantitative analysis, we restricted our focus on brain studies and only on the 497 
ones providing an indication of both the number of subjects and the number of ROIs. 498 
For each study, we computed the sample size as the product between the number of 499 
subjects and the number of ROIs per subject. In this way, we were able to compare 500 
the reported R2 values across measures taking into account the related number of 501 
points actually used for correlation purposes. We note that correlation or regression 502 
analyses run on multiple ROIs and subjects represents a repeated measures 503 
analysis, for which the degrees of freedom computation can be complex; however, 504 
most papers neglected the repeated measures structure of the data and thus the 505 
sample size computation here represents a very approximate and optimistic view of 506 
the precision of each R2 value. 507 
To estimate the variance of each R2 value, we relied on the correlation properties 508 
and the delta method (Lehman, 1999). Let us consider the Pearson’s correlation r of 509 
two variables X and Y with population correlation ⍴. If r is calculated from N random 510 
samples, the sampling variance is (1-⍴2)2/N. Applying the delta method, we then 511 
approximated the variance of R2 as 4R2(1-R2)2/N, assuming R2⍴2.  As we recognise 512 
that some papers computed Spearman correlation, this calculation is again optimistic 513 
and may underestimate the sampling variability of the squared Spearman 514 
correlation. 515 
To estimate the overall effect size in terms of R2 we have to choose how to model 516 
the distribution of true effects given by the data collected from the literature. The two 517 
most common approaches are fixed-effects and mixed-effects models. While the 518 
underlying mathematical model is the same as the one used for linear regression 519 
(more details in the appendix), the assumptions are different: fixed-effects models 520 
assume that all the studies share a common effect size, while mixed-effects models 521 
assume that the effect size across studies is similar but not identical (Raudenbush, 522 
2009). In our case, as the studies have several factors that influence the R2 values 523 
(e.g. histology/microscopy reference, magnetic field strength, pathology model), we 524 
expect a distribution of effect sizes due to inter-study differences. This is why we 525 
proceeded to fit a mixed-effects model to each measure that was featured in more 526 
than two studies. Apart from the effect size distributions, we reported two additional 527 
measures, I2 and tau2: the former expresses as a percentage how much of variability 528 
in a typical study is due to heterogeneity (i.e. the variation in study outcomes 529 
between studies) rather than chance (Higgins & Thompson, 2002), while the latter 530 
can be used to calculate the prediction interval (Raudenbush, 2009), which gives the 531 
expected range for the measure of interest in future studies. We used forest plots to 532 
represent the outcomes, and both the mixed effects estimate of the population 533 
estimated R2, with both a 95% confidence and a (larger) 95% prediction interval. 534 
For the explicit purpose of comparing the effect sizes between different MRI 535 
measures, we conducted a repeated measures meta-regression on every R2 value 536 
recorded. We associated each R2 value with three additional details: (i) the related 537 
variance, as done in the measure-specific mixed-effects models; (ii) the related 538 
study, used as the random intercept (i.e. random variable) to incorporate potential 539 
inter-study variability; and (iii) the related MRI measure, used as the moderator (i.e. 540 
categorical variable) to estimate the differences between measures. In this way, the 541 
meta-regression leads to R2 intervals for each MRI measure, with the same trend as 542 
measure-specific mixed-effects models but with subtle differences. This is because 543 
the meta-regression makes two additional assumptions: first, R2 estimates within the 544 
same study share the same random effects; and second, the between-study 545 
variance is the same for all observations. We then used the meta-regression R2 546 
estimates to compute every possible pairwise comparison between MRI measures 547 
and to identify significantly different pairs using Tukey's test, while controlling the 548 
error rate over all the possible comparisons (Bonferroni correction). 549 
This additional model is necessary, as direct comparisons are not possible with 550 
measure-specific analyses. While the repeated measures meta-regression makes 551 
direct comparisons straightforward, we reported the main R2 estimates based on the 552 
measure-specific mixed-effects models, as they make weaker assumptions. 553 
For visual comparisons, we used the Jupyter notebook provided in the 554 
supplementary materials. For model fitting and forest plots, we used the Metafor 555 
package, version 2.4-0 (Viechtbauer, 2010). 556 
 557 
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Appendix 561 
 562 
Search keywords: 563 
(myelin[Title/Abstract] AND ((magnetic[Title/Abstract] AND resonance[Title/Abstract]) 564 
OR mr[Title/Abstract] OR mri[Title/Abstract])) AND (histology[Title/Abstract] OR 565 
histopathology[Title/Abstract] OR microscopy[Title/Abstract] OR 566 
immunohistochemistry[Title/Abstract] OR histological[Title/Abstract] OR 567 
histologically[Title/Abstract] OR histologic[Title/Abstract] OR 568 
histopathological[Title/Abstract] OR histopathologically[Title/Abstract] OR 569 
histopathologic[Title/Abstract]) 570 
 571 
Results obtained from the Medline database: 688 (03/06/2020) 572 
 573 
 574 
 575 
Figure A1 - PRISMA flowchart for the meta-analysis. 576 
Fixed- and mixed-effects models 577 
 578 
While a traditional linear regression model estimates the error variance from 579 
residuals, in a fixed effects meta-analysis model, each paper’s response and 580 
standard errors, as well as the error variance of the regression model can be directly 581 
computed from the supplied response standard deviations. Specifically, for a (non-582 
meta) regression model we have the 𝑖-th response 𝑦𝑖 modelled with covariate values 583 
𝑥𝑖, 𝑦𝑖 = 𝑥𝑖𝛽 + 𝜀𝑖, where random error has unknown variance Var(𝜀𝑖) = 𝜎
2. In a fixed-584 
effects meta-analysis, we are given 𝑦𝑖 but also 𝑠𝑖, the standard error of 𝑦𝑖, and the 585 
regression model has the same form except the variance is known, Var(𝜀𝑖) = 𝑠𝑖
2, and 586 
the weighted least squares regression can be computed, estimating beta and its 587 
standard error.  A mixed-effects meta-analysis accounts for more variance than what 588 
can be ascribed to the sampling error of the reported outcome.  The regression 589 
model has again the same form, except now the variance is Var(𝜀𝑖) = 𝑠𝑖
2 + 𝜏2, the 590 
sum of the reported squared standard error and the unknown between-study 591 
variance 𝜏2.  Iterative methods are used to estimate 𝜏2 and, once estimated, 592 
a weighted least squares regression can be computed.   The parameter 𝜏2 can be 593 
interpreted as the variance of noise-free (hypothetical, zero standard error) results 594 
from the population of all possible studies. The importance of 𝜏2 can also be gauged 595 
by 𝐼2, the proportion of variance due to random inter-study differences (i.e. 1 − 𝐼2 is 596 
the proportion attributable to random sampling error of each study) (Higgins & 597 
Thompson, 2002). 598 
 599 
  600 
Table A1 - Selected studies for qualitative analysis. 601 
 602 
Study MRI 
measure(s) 
Histology/microscopy 
measure 
Tissue Condition Focus 
(Schmierer, 
Scaravilli, 
Altmann, 
Barker, & 
Miller, 2004) 
T1, MTR Histology - LFB Human Multiple sclerosis Brain 
(Odrobina, 
Lam, Pun, 
Midha, & 
Stanisz, 
2005) 
T1, T2, 
T2int, 
MWF, 
M0m, MTR 
Microscopy - Myelin 
fraction 
Animal - 
Rat 
Demyelination - 
Tellurium 
PN 
(Pun et al., 
2005) 
T1, T2int, 
MWF 
Microscopy - Myelin 
fraction 
Animal - 
Rat 
Demyelination - 
Tellurium 
PN 
(Laule et al., 
2006) 
MWF Histology - LFB Human Multiple sclerosis Brain 
(Schmierer, 
Tozer, et al., 
2007) 
T1, MTR, 
MPF, T2m 
Histology - LFB Human Multiple sclerosis Brain 
(Schmierer, 
Wheeler-
Kingshott, et 
al., 2007) 
FA, MD Histology - LFB Human Multiple sclerosis Brain 
(Jito et al., 
2008) 
FA Microscopy - Myelin 
sheath area 
Animal - 
Mouse 
Healthy Brain 
(Kozlowski et 
al., 2008) 
MWF, FA, 
AD, RD, 
MD 
Immunohistochemistry 
- MBP 
Animal - 
Rat 
Injury - Dorsal 
columnar 
transection 
SC 
(Laule et al., 
2008) 
MWF Histology - LFB Human Multiple sclerosis Brain 
(Schmierer 
et al., 2008) 
T1, T2, 
MTR, 
Histology - LFB Human Multiple sclerosis Brain 
MPF, MD, 
FA, AD, 
RD 
(Wu et al., 
2008) 
T2 Histology - LFB Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Zaaraoui et 
al., 2008) 
MTR Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Takagi et 
al., 2009) 
FA, AD EM - Myelin thickness Animal - 
Rat 
Degeneration - 
Contusive injury 
PN 
(S. Wang et 
al., 2009) 
FA, RD Histology - LFB Animal - 
Rat 
Ischemia - Induced 
hypoxia 
Brain 
(Zhang et al., 
2009) 
RD Histology - LFB Animal - 
Rat 
Injury - Dorsal 
columnar 
transection 
SC 
(Schmierer 
et al., 2010) 
MTR, T2 Histology - LFB Human Multiple sclerosis Brain 
(Fatemi et 
al., 2011) 
MTR Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Ischemia - Induced 
hypoxia 
Brain 
(Laule et al., 
2011) 
MWF Immunohistochemistry 
- MBP 
Human Multiple sclerosis Brain 
(Underhill, 
Rostomily, 
Mikheev, 
Yuan, & 
Yarnykh, 
2011) 
MPF Histology - LFB Animal - 
Mouse 
Healthy Brain 
(Chandran et 
al., 2012) 
FA, RD Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Tardif et al., 
2012) 
T1, T2, 
MTR, PD 
Immunohistochemistry 
- MBP 
Human Multiple sclerosis Brain 
(Fjaer et al., 
2013) 
MTR Immunohistochemistry 
- PLP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(K. D. MWF, MPF Microscopy - Myelin Animal - Edema - SC 
Harkins, 
Valentine, 
Gochberg, & 
Does, 2013) 
fraction Rat Hexaclorophene 
(Janve et al., 
2013) 
MPF, R1a, 
k_ba, FA, 
RD, MD, 
AD 
Histology - LFB Animal - 
Rat 
Demyelination - 
Lipopolysaccharide 
Brain 
(Thiessen et 
al., 2013) 
MPF, R1f, 
k_fm, 
k_mf, T2f, 
T2m, MD, 
RD, AD, 
FA, T1, T2 
EM - Myelin thickness Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Kozlowski, 
Rosicka, Liu, 
Yung, & 
Tetzlaff, 
2014) 
MWF Immunohistochemistry 
- MBP 
Animal - 
Rat 
Injury - Dorsal 
columnar 
transection 
SC 
(X. Wang et 
al., 2014) 
RD, RD-
DBSI 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Autoimmune 
encephalomyelitis 
SC 
(Fjaer, Bo, 
Myhr, 
Torkildsen, & 
Wergeland, 
2015) 
MTR Immunohistochemistry 
- PLP 
Animal - 
Mouse 
Demyelination - 
Autoimmune 
encephalomyelitis 
Brain 
(Seehaus et 
al., 2015) 
FA, RD, 
MD 
Histology - Silver Human Healthy Brain 
(Turati et al., 
2015) 
MPF Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Y. Wang et 
al., 2015) 
RD-DBSI Histology - LFB Human Multiple sclerosis SC 
(Aojula et al., 
2016) 
FA, AD, 
RD, MD 
Immunohistochemistry 
- MBP 
Animal - 
Rat 
Hydrocephalus Brain 
(Hakkarainen 
et al., 2016) 
T1, T2, 
MTR, T1p, 
T2p, RAFF 
Histology - Gold 
chloride 
Animal - 
Rat 
Healthy Brain 
(Jelescu et 
al., 2016) 
RD, RK, 
AWF, Rde, 
T2, MTR 
EM - Myelin fraction Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Kelm et al., 
2016) 
MD, RD, 
MK, RK, 
AWF 
EM - Myelin fraction Animal - 
Mouse 
Demyelination - 
Knockout 
Brain 
(Reeves et 
al., 2016) 
T1, T2 Immunohistochemistry 
- MBP 
Human Epilepsy Brain 
(Tu et al., 
2016) 
FA, AD, 
RD, MD, 
MTR 
Immunohistochemistry 
- MBP 
Animal - 
Rat 
Traumatic brain 
injury 
Brain 
(Chang et 
al., 2017) 
FA, AD, 
RD, MD 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Healthy Brain 
(Chen, 
Holmes, Liu, 
Tetzlaff, & 
Kozlowski, 
2017) 
MWF EM - Myelin fraction Animal - 
Rat 
Injury - Dorsal 
columnar 
transection 
SC 
(M. Y. 
Khodanovich 
et al., 2017) 
MPF Histology - LFB Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Lehto, 
Albors, et al., 
2017) 
RAFF, 
MTR, 
T1sat, FA, 
MD, AD, 
RD 
Histology - Gold 
chloride 
Animal - 
Rat 
Demyelination - 
Lipopolysaccharide 
Brain 
(Lehto, 
Sierra, & 
MTR Histology - Gold 
chloride 
Animal - 
Rat 
Traumatic brain 
injury 
Brain 
Grohn, 2017) 
(van Tilborg 
et al., 2018) 
FA Immunohistochemistry 
- MBP 
Animal - 
Rat 
White matter injury Brain 
(Beckmann 
et al., 2018) 
MTR Histology - LFB Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Berman, 
West, Does, 
Yeatman, & 
Mezer, 2018) 
MTV EM - Myelin fraction Animal - 
Mouse 
Demyelination - 
Knockout 
Brain 
(Hametner et 
al., 2018) 
R2*, T1, 
QSM 
Histology - LFB Human Vascular diseases Brain 
(Praet et al., 
2018) 
MK, RK, 
AK, FA, 
MD, RD, 
AD 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Amyloidosis Brain 
(Wendel et 
al., 2018) 
FA, AD, 
RD, MD 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Traumatic brain 
injury 
Brain 
(West et al., 
2018) 
MPF, 
MWF, 
MVF-T2, 
MVF-MT 
EM - Myelin fraction Animal - 
Mouse 
Demyelination - 
Knockout 
Brain 
(Yano et al., 
2018) 
FA, RD, 
MD 
Immunohistochemistry 
- PLP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Abe et al., 
2019) 
FA, RD, 
AD 
Microscopy - Myelin 
thickness 
Animal - 
Mouse 
Optogenetic 
stimulation 
Brain 
(Duhamel et 
al., 2019) 
ihMTR, 
MTR 
Microscopy - 
Fluorescence 
Animal - 
Mouse 
Healthy Brain 
(M. 
Khodanovich 
et al., 2019) 
MPF Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Mollink et 
al., 2019) 
FA Immunohistochemistry 
- MBP 
Human Amyotrophic lateral 
sclerosis 
Brain 
(Peters et al., FA, MD Histology - LFB Human Tuberous sclerosis Brain 
2019) complex 
(Pol et al., 
2019) 
QSM, FA, 
MD 
Histology - 
Solochrome 
Animal - 
Mouse 
Healthy Brain 
(Soustelle et 
al., 2019) 
MPF, RD, 
MWF, 
rSPF 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Demyelination - 
Cuprizone 
Brain 
(Guglielmetti 
et al., 2020) 
MTR, 
MTR-UTE 
Immunohistochemistry 
- MBP 
Animal - 
Mouse 
Healthy Brain 
 603 
  604 
Supplementary material 605 
 606 
To reproduce our results, we provided as supplementary material: 607 
- Source Data 1: a spreadsheet in xlsx format containing all the data and details 608 
collected for the studies considered in this systematic review; 609 
- Supplementary File 1: A multimedia file in HTML format containing an 610 
interactive version of the figures in this manuscript plus additional ones; 611 
- Source Code 1: A Jupyter notebook in ipynb format containing the Python 612 
code used to process the data, run the analyses and generate all the figures. 613 
In order to execute the notebook, the Python (3.7) and R (3.6) interpreters are 614 
required, as well as the R packages metafor (2.4) and multcomp (1.4), and the 615 
following Python packages: 616 
- numpy (1.18.4); 617 
- pandas (0.25.3); 618 
- plotly (4.8.1); 619 
- rpy2 (3.3.4); 620 
- xlrd (1.2.0). 621 
The notebook assumes that the spreadsheet is in the same path as the notebook 622 
itself. More details are provided at the following link:  623 
https://github.com/matteomancini/myelin-meta-analysis 624 
 625 
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